COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron SurgeWilla Cochran, Robin K. Avery, Heba H. Mostafa et al.|Transplantation|2022Cited by 25
Persistent SARS-CoV-2–specific immune defects in kidney transplant recipients following third mRNA vaccine doseWilliam A. Werbel, Dorry L. Segev, Andrew H. Karaba et al.|American Journal of Transplantation|2023Cited by 19
Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant RecipientsSonsoles Salto‐Alejandre, Robin K. Avery, Willa Cochran et al.|Transplant Infectious Disease|2024Cited by 0
Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 TherapeuticsEvan M. Bloch, Seema Mehta Steinke, Tania Jain et al.|UNC Libraries|2025Cited by 0